Business Context and Reporting Period
DT Cloud Star Acquisition Corporation (DTCS), a Cayman Islands exempted company and emerging growth company, filed this Form 8-K on February 2, 2026. The filing announces the entry into a Business Combination Agreement (BCA) with PrimeGen US, Inc. (the "Company"). The transaction involves a redomestication merger of DTCS into a Delaware subsidiary (Purchaser) followed by an acquisition merger of PrimeGen US into the surviving entity. The combined entity will be listed on The Nasdaq Stock Market LLC.
Key Financial Metrics and Transaction Terms
The filing details the structure of the merger consideration rather than historical financial performance metrics such as revenue or cash flow, as DTCS is a special purpose acquisition company (SPAC).
- Merger Consideration Value: The aggregate value of the Purchaser Class A Common Stock to be issued to PrimeGen US stockholders is set at $1,489,800,000, subject to adjustments for outstanding warrants and stock options of the Company.
- Valuation Basis: The purchase price is calculated by dividing the aggregate value by the redemption price per share.
- Non-Redemption Warrants: Upon closing, 1,931,900 new warrants will be issued to eligible shareholders who do not redeem their shares. These warrants have an exercise price of $2.00 per share and are exercisable starting six months after closing for a two-year period.
- Capital Expenditure Limits: Prior to closing, DTCS is restricted from making capital expenditures exceeding $2.5 million per project or $10 million in aggregate.
- Liability Limits: DTCS is restricted from incurring liabilities exceeding $100,000 individually or in aggregate during the interim period, excluding ordinary course expenses.
Material Changes and Transaction Structure
The primary material change is the execution of the BCA, which fundamentally alters the corporate structure and business focus of DTCS.
- Redomestication: DTCS will merge into DTSQ Purchaser Inc., a Delaware corporation, changing its jurisdiction of incorporation.
- Security Conversion: Existing DTCS Units will separate into ordinary shares and rights. Ordinary shares will convert one-for-one into Purchaser Class A Common Stock. Rights will convert into rights to receive 1/9 of one share of Purchaser Class A Common Stock.
- Support Agreements: Significant Company Holders (directors and 10%+ owners) and DTCS Insiders (Sponsor and officers) have entered into support agreements to vote in favor of the transaction and refrain from redeeming shares.
- Lock-Up Provisions: The Sponsor and certain Company stockholders are subject to a lock-up period of 180 days post-closing, unless the stock price exceeds $12.00 per share for 20 trading days within a 30-day period (starting 90 days post-closing) or a change in control occurs.
Guidance, Outlook, Risks, and Contingencies
The filing contains extensive forward-looking statements regarding the anticipated benefits, timing, and financial performance of the combined company, which are subject to significant risks.
- Closing Conditions: The transaction is contingent upon shareholder approvals from both DTCS and PrimeGen US, SEC effectiveness of the registration statement, Nasdaq listing approval, and the absence of a Material Adverse Effect on the Company.
- Termination Rights: The agreement may be terminated if the closing does not occur by the "Outside Date" of October 26, 2026, unless extended by mutual agreement. Either party may terminate for material breach, failure to obtain approvals, or if a governmental authority permanently prohibits the transaction.
- Key Risks: Risks include failure to complete the business combination by the deadline, redemptions exceeding anticipated levels, failure to meet Nasdaq listing standards, disruption of operations, and the need for additional capital post-combination.
- Regulatory Disclosure: The filing includes a Regulation FD disclosure referencing a presentation (Exhibit 99.1) regarding the business combination, which is not deemed "filed" for liability purposes.
Investor Verification Checklist
- Verify the final redemption price per share to calculate the exact number of shares to be issued to PrimeGen US stockholders.
- Confirm the level of shareholder redemptions, as this impacts the cash available to the combined company and the issuance of Non-Redemption Warrants.
- Review the upcoming Proxy Statement/Prospectus (Form S-4) for detailed financial projections, risk factors, and the definitive terms of the transaction.
- Monitor the status of Nasdaq listing approval and SEC registration statement effectiveness as critical closing conditions.
- Assess the impact of the $12.00 per share stock price trigger on the 180-day lock-up period for insiders and significant holders.